Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Popov, Alexey ^a   Szabo, Arpad ^a   Mandys, Václav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Internal control; MiRNA; Pancreatic cancer; Pancreatic ductal adenocarcinoma; RT qPCR (reverse transcription quantitative PCR)

Indexed keywords

MICRORNA; MICRORNA 148A; MICRORNA 155; MICRORNA 16; MICRORNA 196A; MICRORNA 21; MICRORNA 217; MICRORNA 39; MICRORNA 96; SMALL NUCLEOLAR RNA; SMALL NUCLEOLAR RNA U6; SMALL NUCLEOLAR RNA U91; UNCLASSIFIED DRUG; MIRN155 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN217 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; MEASUREMENT ACCURACY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATIC TISSUE; PANCREATICODUODENECTOMY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; ADENOCARCINOMA; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PROCEDURES; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL NUCLEOLAR;

EID: 84945151285     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1785-9     Document Type: Article

References (45)

1. Hidalgo M. Pancreatic cancer. The New England journal of medicine. 2010;362(17):1605-17. doi: 10.1056/NEJMra0901557.
2. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. P Natl Acad Sci USA. 2008;105(30):10513-8. doi: 10.1073/pnas.0804549105.
3. Sassen S, Miska EA, Caldas C. MicroRNA - implications for cancer. Virchows Arch. 2008;452(1):1-10. doi: 10.1007/s00428-007-0532-2.
4. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metast Rev. 2009;28(3-4):369-78. doi: 10.1007/s10555-009-9188-5.
5. Zhang BH, Pan XP, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1-12. doi: 10.1016/j.ydbio.2006.08.028.
6. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev. 2009;84(1):55-71. doi: 10.1111/j.1469-185X.2008.00061.x.
7. Lee EJ, Gusev Y, Jiang JM, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120(5):1046-54. doi: 10.1002/Ijc.22394.
8. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, et al. MicroRNA-21 Is Induced Early in Pancreatic Ductal Adenocarcinoma Precursor Lesions. Clin Chem. 2010;56(4):603-12. doi: 10.1373/clinchem.2009.137364.
9. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009;8(5):1067-74. doi: 10.1158/1535-7163.Mct-08-0592.
10. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 Expression Is an Early Event in the Multistep Progression of Pancreatic Adenocarcinoma. Pancreatology. 2010;10(1):66-73. doi: 10.1159/000231984.
11. Habbe N, Koorstra JBM, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340-6. doi: 10.4161/Cbt.8.4.7338.
12. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 MicroRNA family. Cell. 2005;120(5):635-47. doi: 10.1016/j.cell.2005.01.014.
13. Yu SN, Lu ZH, Liu CZ, Meng YX, Ma YH, Zhao WG, et al. miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer. Cancer Res. 2010;70(14):6015-25. doi: 10.1158/0008-5472.Can-09-4531.
14. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010;31(10):1726-33. doi: 10.1093/carcin/bgq160.
15. Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, et al. The Silencing of MicroRNA 148a Production by DNA Hypermethylation Is an Early Event in Pancreatic Carcinogenesis. Clin Chem. 2010;56(7):1107-18. doi: 10.1373/clinchem.2010.144709.
16. Mardin W, Mees ST. MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma? Ann Surg Oncol. 2009;16(11):3183-9. doi: 10.1245/s10434-009-0623-1.
17. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. Rna. 2008;14(5):844-52. doi: 10.1261/Rna.939908.
18. Xiang MQ, Zeng Y, Yang RR, Xu HF, Chen Z, Zhong J, et al. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Bioph Res Co. 2014;454(1):210-4. doi: 10.1016/j.bbrc.2014.10.064.
19. Hansen CN, Ketabi Z, Rosenstierne MW, Palle C, Boesen HC, Norrild B. Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development. Apmis. 2009;117(1):53-9. doi: 10.1111/j.1600-0463.2008.00015.x.
20. Qi LQ, Bart J, Tan LP, Platteel I, van der Sluis T, Huitema S et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. Bmc Cancer. 2009;9. doi: 10.1186/1471-2407-9-163.
21. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104(41):16170-5. doi: 10.1073/pnas.0703942104.
22. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010;126(1):73-80. doi: 10.1002/ijc.24687.
23. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-52. doi: 10.1038/sj.onc.1210228.
24. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama. 2007;297(17):1901-8. doi: 10.1001/jama.297.17.1901.
25. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem. 2008;54(10):1716-24. doi: 10.1373/clinchem.2008.109603.
26. Huang F, Tang J, Zhuang X, Zhuang Y, Cheng W, Chen W, et al. MiR-196a promotes pancreatic cancer progression by targeting nuclear factor kappa-B-inhibitor alpha. PloS one. 2014;9(2):e87897. doi: 10.1371/journal.pone.0087897.
27. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World journal of surgery. 2009;33(4):698-709. doi: 10.1007/s00268-008-9833-0.
28. Link A, Becker V, Goel A, Wex T, Malfertheiner P. Feasibility of Fecal MicroRNAs as Novel Biomarkers for Pancreatic Cancer. PloS one. 2012;7(8):e42933. doi: 10.1371/journal.pone.0042933.
29. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(2):534-45. doi: 10.1158/1078-0432.CCR-11-0679.
30. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer prevention research. 2009;2(9):807-13. doi: 10.1158/1940-6207.CAPR-09-0094.
31. Hong TH, Park IY. MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. Annals of surgical treatment and research. 2014;87(6):290-7. doi: 10.4174/astr.2014.87.6.290.
32. Kent OA, Mullendore M, Wentzel EA, Lopez-Romero P, Tan AC, Alvarez H, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009;8(21):2013-24.
33. Feng J, Yu JB, Pan XL, Li ZL, Chen Z, Zhang WJ, et al. HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget. 2014;5(14):5832-44.
34. Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, et al. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J Exp Clin Canc Res. 2013;32:71. doi: 10.1186/1756-9966-32-71.
35. Zhang R, Li M, Zang W, Chen X, Wang Y, Li P, et al. MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(1):837-44. doi: 10.1007/s13277-013-1115-2.
36. Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern Pathol. 2012;25(12):1609-22. doi: 10.1038/modpathol.2012.122.
37. Wang J, Raimondo M, Guha S, Chen JY, Diao LX, Dong XQ, et al. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer. 2014;5(8):696-705. doi: 10.7150/Jca.10094.
38. Nakata K, Ohuchida K, Mizumoto K, Kayashima T, Ikenaga N, Sakai H, et al. MicroRNA-10b is overexpressed in pancreatic cancer, promotes its invasiveness, and correlates with a poor prognosis. Surgery. 2011;150(5):916-22. doi: 10.1016/j.surg.2011.06.017.
39. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther. 2008;7(3):464-73. doi: 10.1158/1535-7163.MCT-07-2272.
40. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753-6. doi: 10.1158/0008-5472.CAN-04-0637.
41. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Brit J Cancer. 2011;104(7):1168-77. doi: 10.1038/sj.bjc.6606076.
42. Appaiah HN, Goswami CP, Mina LA, Badve S, Sledge GW, Liu YL, et al. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011;13(5):R86. doi: 10.1186/Bcr2943.
43. McDermott AM, Kerin MJ, Miller N. Identification and Validation of miRNAs as Endogenous Controls for RQ-PCR in Blood Specimens for Breast Cancer Studies. PloS one. 2013;8(12):e83718. doi: 10.1371/journal.pone.0083718.
44. Liu JQ, Gao J, Du YQ, Li ZS, Ren Y, Gu JJ, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012;131(3):683-91. doi: 10.1002/Ijc.26422.
45. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-22. doi: 10.1373/clinchem.2008.112797.